• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

CRISPR-Based HIV Gene Therapy Administered To First Human Patient

September 22, 2022 by Deborah Bloomfield

In a clinical trial, the first patient has received a single dose of a new human immunodeficiency virus (HIV) gene editing therapy, researchers at the Lewis Katz School of Medicine at Temple University and Excision BioTherapeutics, Inc have reported.

In a collaborative effort, the researchers are currently running a phase 1/2 clinical trial to evaluate the safety and efficacy of their therapy, called EBT-101, which is based on gene editing technology known as CRISPR. 

Advertisement

“Nearly 40 million people worldwide suffer from the effects of HIV, and more than 40 years after the discovery of HIV/AIDS, there still are no curative treatments,” said Professor Kamel Khalili, who helped lead the trial, in a statement. 

“EBT-101 can potentially address long-standing unmet needs of individuals living with HIV/AIDS by removing viral DNA from their cells, thereby eradicating infection.”

When HIV infects, it takes long-term hold and hides from the immune system in cells, compromising the patient’s immunity over time and eventually leading to the development of AIDS – the progressive failure of a patient’s immune system. There is currently no cure for HIV, but various treatments and medications can help manage the infection and slow or prevent the progression of the disease.

Advertisement



The therapy currently being trialed, which uses CRISPR gene editing to remove HIV viral DNA from infected cells, is a major step toward finding a therapeutic cure.

“We are well-positioned to collect key data that will enable our efforts to translate the success this approach has shown in animal models to human clinical trial participants,” Khalili added. “We look forward to investigating this hypothesis through the EBT-101 clinical program and are pleased that the EBT-101 Phase 1/2 trial is proceeding as planned.”

The first patient to receive a single dose of EBT-101 in the current trial is currently under medical supervision and will soon be assessed to see if there is any viral rebound and whether the single curative treatment worked as planned. This will be a deciding factor in whether or not the patient is able to stop their current antiretroviral therapy in the future.

Advertisement

“The official start of the Phase 1/2 clinical trials for EBT-101 brings us one extremely significant step closer to creating a potential cure for HIV/AIDS,” said Dr Amy J. Goldberg, Interim Dean of the Katz School of Medicine. “This amazing milestone speaks to the exceptional research acumen and scientific knowledge of Drs. Khalili and Burdo and their teams – outstanding members of the Temple family.”

For further details, you can view the clinical trial information at ClinicalTrials and follow its progress.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. ‘Hadestown’ marks return of Broadway musicals after 18-month shutdown
  2. Macron says French forces killed Islamic State leader in Sahara
  3. Italy’s Draghi to meet Greta Thunberg at Milan climate talks – source
  4. How “Diamond Dust” Sparkles In The Sky In Sub-Zero Temperatures

Source Link: CRISPR-Based HIV Gene Therapy Administered To First Human Patient

Filed Under: News

Primary Sidebar

  • Unethical Experiments: When Scientists Really Should Have Stopped What They Were Doing Immediately
  • The First Humans Were Hunted By Leopards And Weren’t The Apex Predators We Thought They Were
  • Earth’s Passage Through The Galaxy Might Be Written In Its Rocks
  • What Is An Einstein Cross – And Why Is The Latest One Such A Unique Find?
  • If We Found Life On Mars, What Would That Mean For The Fermi Paradox And The Great Filter?
  • The Longest Living Mammals Are Giants That Live Up To 200 Years In The Icy Arctic
  • Entirely New Virus Detected In Bat Urine, And It’s Only The 4th Of Its Kind Ever Isolated
  • The First Ever Full Asteroid History: From Its Doomed Discovery To Collecting Its Meteorites
  • World’s Oldest Pachycephalosaur Fossil Pushes Back These Dinosaurs’ Emergence By 15 Million Years
  • The Hole In The Ozone Layer Is Healing And On Track For Full Recovery In The 21st Century, Thanks To Science
  • First Sweet Potato Genome Reveals They’re Hybrids With A Puzzling Past And 6 Sets Of Chromosomes
  • Why Is The Top Of Canada So Sparsely Populated? Meet The “Canadian Shield”
  • Humans Are In The Middle Of “A Great Evolutionary Transition”, New Paper Claims
  • Why Do Some Toilets Have Two Flush Buttons?
  • 130-Year-Old Butter Additive Discovered In Danish Basement Contains Bacteria From The 1890s
  • Prehistoric Humans Made Necklaces From Marine Mollusk Fossils 20,000 Years Ago
  • Zond 5: In 1968 Two Soviet Steppe Tortoises Beat Humans To Orbiting Around The Moon
  • Why Cats Adapted This Defense Mechanism From Snakes
  • Mother Orca Seen Carrying Dead Calf Once Again On Washington Coast
  • A Busy Spider Season Is Brewing: Why This Fall Could See A Boom Of Arachnid Activity
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version